207 related articles for article (PubMed ID: 33067920)
41. Different pathological roles of toll-like receptor 9 on mucosal B cells and dendritic cells in murine IgA nephropathy.
Kajiyama T; Suzuki Y; Kihara M; Suzuki H; Horikoshi S; Tomino Y
Clin Dev Immunol; 2011; 2011():819646. PubMed ID: 21765852
[TBL] [Abstract][Full Text] [Related]
42. Expression and correlation analysis of IL-4, IFN-γ and FcαRI in tonsillar mononuclear cells in patients with IgA nephropathy.
Chen X; Liu H; Peng Y; He L; Zhang Y; Xie Y; Peng X; Liu C; Liu F
Cell Immunol; 2014; 289(1-2):70-5. PubMed ID: 24732061
[TBL] [Abstract][Full Text] [Related]
43. [Role of IgG antibody to galactose-deficient IgA1 in children with IgA nephropathy].
Zhou N; Zhang H; Liu XR; Sun Q; Meng Q; Chen Z; Shen Y
Zhonghua Er Ke Za Zhi; 2017 Sep; 55(9):663-667. PubMed ID: 28881511
[No Abstract] [Full Text] [Related]
44. Reconstitution of immunological imbalance in SCID mice given tonsillar mononuclear cells from patients with IgA nephropathy.
Kusakari C; Takasaka T
Acta Otolaryngol Suppl; 1993; 508():19-22. PubMed ID: 8285038
[TBL] [Abstract][Full Text] [Related]
45. Expression of IgA class switching gene in tonsillar mononuclear cells in patients with IgA nephropathy.
Liu H; Peng Y; Liu F; Xiao W; Zhang Y; Li W
Inflamm Res; 2011 Sep; 60(9):869-78. PubMed ID: 21614556
[TBL] [Abstract][Full Text] [Related]
46. Pathogenic role of glycan-specific IgG antibodies in IgA nephropathy.
Zhao YF; Zhu L; Liu LJ; Shi SF; Lv JC; Zhang H
BMC Nephrol; 2017 Sep; 18(1):301. PubMed ID: 28969604
[TBL] [Abstract][Full Text] [Related]
47. The role of polymeric IgA in complement-mediated solubilization of IgG and IgA immune complexes.
Schena FP; Pastore A; Montinaro V
Am J Kidney Dis; 1988 Nov; 12(5):433-6. PubMed ID: 3055971
[TBL] [Abstract][Full Text] [Related]
48. Antimouse laminin antibodies in IgA nephropathy and various glomerular diseases.
Shinkai Y; Karai M; Osawa G; Sato M; Koshikawa S
Nephron; 1990; 56(3):285-96. PubMed ID: 1706484
[TBL] [Abstract][Full Text] [Related]
49. In vitro immunoglobulin isotype suppression in immunoglobulin A nephropathy.
Allen AC; Layward L; Harper SJ; Feehally J
Exp Nephrol; 1994; 2(3):166-70. PubMed ID: 7922268
[TBL] [Abstract][Full Text] [Related]
50. Murine Models of Human IgA Nephropathy.
Suzuki H; Suzuki Y
Semin Nephrol; 2018 Sep; 38(5):513-520. PubMed ID: 30177023
[TBL] [Abstract][Full Text] [Related]
51. Fundamental characteristics of the expressed immunoglobulin VH and VL repertoire in different canine breeds in comparison with those of humans and mice.
Steiniger SC; Dunkle WE; Bammert GF; Wilson TL; Krishnan A; Dunham SA; Ippolito GC; Bainbridge G
Mol Immunol; 2014 May; 59(1):71-8. PubMed ID: 24509215
[TBL] [Abstract][Full Text] [Related]
52. Detection of immunoglobulin depositions by immunofluorescence and/or immunoperoxidase (P-AP method) in patients with IgA nephropathy.
Miura M; Tomino Y; Nomoto Y; Sakai H; Osamura Y
Tokai J Exp Clin Med; 1987 Dec; 12(5-6):343-7. PubMed ID: 3334190
[TBL] [Abstract][Full Text] [Related]
53. Antibodies to polyclonal IgA, IgA1, and IgA2 and isotype-specific immune complexes in IgA nephropathy.
Jones CL; Hosking CS; Kincaid-Smith P; Powell HR; Richardson SC; Sennhauser FH; Roberton DM
J Clin Immunol; 1989 Jul; 9(4):306-12. PubMed ID: 2671010
[TBL] [Abstract][Full Text] [Related]
54. IgA nephropathy: characterization of IgG antibodies specific for galactose-deficient IgA1.
Suzuki H; Moldoveanu Z; Hall S; Brown R; Julian BA; Wyatt RJ; Tomana M; Tomino Y; Novak J; Mestecky J
Contrib Nephrol; 2007; 157():129-33. PubMed ID: 17495450
[TBL] [Abstract][Full Text] [Related]
55. Immunoglobulin-antiimmunoglobulin interactions and immune complexes in IgA nephropathy.
Jackson S
Am J Kidney Dis; 1988 Nov; 12(5):425-9. PubMed ID: 3055969
[TBL] [Abstract][Full Text] [Related]
56. Application of Oxford classification, and overexpression of transforming growth factor-β1 and immunoglobulins in immunoglobulin A nephropathy: correlation with World Health Organization classification of immunoglobulin A nephropathy in a Chinese patient cohort.
Meng H; Zhang L; E X; Ye F; Li H; Han C; Yamakawa M; Jin X
Transl Res; 2014 Jan; 163(1):8-18. PubMed ID: 23891568
[TBL] [Abstract][Full Text] [Related]
57. The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy.
Rizk DV; Maillard N; Julian BA; Knoppova B; Green TJ; Novak J; Wyatt RJ
Front Immunol; 2019; 10():504. PubMed ID: 30941137
[TBL] [Abstract][Full Text] [Related]
58. A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy.
Myette JR; Kano T; Suzuki H; Sloan SE; Szretter KJ; Ramakrishnan B; Adari H; Deotale KD; Engler F; Shriver Z; Wollacott AM; Suzuki Y; Pereira BJG
Kidney Int; 2019 Jul; 96(1):104-116. PubMed ID: 31027890
[TBL] [Abstract][Full Text] [Related]
59. Aberrantly glycosylated IgA1 as a factor in the pathogenesis of IgA nephropathy.
Tanaka M; Seki G; Someya T; Nagata M; Fujita T
Clin Dev Immunol; 2011; 2011():470803. PubMed ID: 21318178
[TBL] [Abstract][Full Text] [Related]
60. IgM, IgG, and IgA Influenza-Specific Plasma Cells Express Divergent Transcriptomes.
Price MJ; Hicks SL; Bradley JE; Randall TD; Boss JM; Scharer CD
J Immunol; 2019 Oct; 203(8):2121-2129. PubMed ID: 31501259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
